問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

List

1334Cases

2020-06-01 - 2022-01-31

Phase III

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting9Sites

2019-06-14 - 2021-11-30

Phase III

ATLAS-PPX: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in patients with hemophilia A and B previously receiving factor or bypassing agent prophylaxis.

  • Condition/Disease

    Acquired hemophilia

  • Test Drug

    Fitusiran

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2019-09-01 - 2019-08-06

Phase III

Regarding tislelizumab (BGB-A317) combined with chemotherapy and radiotherapy followed by tislelizumab monotherapy for use in newly diagnosed, locally advanced, unresectable stage III non-small cell lung cancer subjects for a phase 3, random assignment, double blind, Placebo controlled trial.

  • Condition/Disease

    NSCLC

  • Test Drug

    Tislelizumab

Participate Sites
8Sites

Recruiting3Sites

Terminated5Sites

2019-06-15 - 2023-09-14

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy

  • Condition/Disease

    IgA Nephropathy

  • Test Drug

    Cemdisiran (ALN-CC5)

Participate Sites
6Sites

Recruiting6Sites

2021-07-01 - 2023-02-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2015-12-01 - 2020-04-30

Phase III

A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Test Drug

    Pexastimogene Devacirepvec (Pexa Vec)

Participate Sites
6Sites

Terminated6Sites

2014-05-01 - 2017-04-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2018-03-01 - 2020-05-31

Phase III

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

  • Condition/Disease

    Hemophilia A or B

  • Test Drug

    Fitusiran (ALN-AT3SC)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

張家堯
Taipei Medical University Hospital

Division of Pediatrics

2018-03-01 - 2022-12-13

Phase III

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN).

  • Condition/Disease

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • Test Drug

    Nivolumab

Participate Sites
7Sites

Not yet recruiting1Sites

Terminated3Sites

謝清昀
China Medical University Hospital-Taipei

未分科

2016-09-12 - 2019-12-05

Phase III

Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

  • Condition/Disease

    NSCLC

  • Test Drug

    MYL-1402O

Participate Sites
6Sites

Terminated6Sites

1 95 96 97 98 99 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB